The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis.
Idevaldo Floriano, Antônio Silvinato, Wanderley Marques Bernardo
Revista da Associação Médica Brasileira May 15, 2023 DOI: 10.1590/1806-9282.2023d694 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review protocol Randomized Peer reviewed |
|---|---|
| Interventions | Esketamine standard care (antidepressants) placebo |
| Duration | Minimum 25 days follow-up |
| Topics | Depression Ketamine Esketamine |
| Keywords | Humans Suicidal ideation |
| Key findings | The protocol outlines a planned systematic review to assess whether esketamine plus standard care improves depression in patients with major depression and suicidal ideation compared with placebo plus standard care, drawing on randomized controlled trials and observational studies with at least 25 days of follow-up. No findings are reported. |
Abstract
Eligibility criteria were as follows:1. Patients with major depression and suicidal ideation.2. Esketamine treatment plus standard care (antidepressants) compared to placebo plus standard care.3. Outcomes -improvement in the state of depression, evaluated in appropriate scores.4. Included randomized controlled trials (RCTs) and observational studies. 5.No restrictions on publication date and language.6. Full text available for access.7. Follow-up time: minimum 25 days.The search for evidence will be carried out in the Medline/ PubMed and Central Cochrane virtual scientific information base, using the following search strategy: (Depressive Disorder OR Depressive Disorder, Major OR Depressive Disorder, Treatment-Resistant) AND Esketamine AND Random*.The search in these databases was carried out until the month of
Comparable studies
Other systematic reviews and meta-analyses on esketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis Adults with unipolar or bipolar major depression | 2020 | Systematic review and meta-analysis | n = 1,877 |
| The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. Participants in randomized controlled trials of ketamine for suicidal ideation | 2020 | Systematic review and meta-analysis | n = 197 |
| Efficacy of Esketamine Augmentation in Major Depressive Disorder Patients with major depressive disorder who are treatment-resistant or acutely suicidal | 2020 | Systematic review and meta-analysis | n = 774 |
| Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. Patients with treatment-resistant major depressive disorder | 2025 | Systematic review and meta-analysis | |
| EFFICACY AND SAFETY OF RACEMIC KETAMINE AND ESKETAMINE FOR DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS Adults with unipolar or bipolar major depression | 2022 | Systematic review and meta-analysis | n = 2,903 |
Citations in the library
Cited by 7
- Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. American Journal of Psychiatry March 1, 2025
- Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience) Journal of Personalized Medicine April 1, 2025
- Rapid and long-lasting effects of subcutaneous esketamine on suicidality: An open-label study in patients with treatment-resistant depression. Journal of Psychiatric Research August 1, 2024
- Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study. Journal of Affective Disorders January 15, 2025
- Clinical trials since 2020 of rapid anti-suicidal ideation effects of ketamine and its enantiomers: a systematic review. Translational Psychiatry February 6, 2025
and 2 more in the library
Cites 18
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study American Journal of Psychiatry May 21, 2019
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
- Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression JAMA Psychiatry December 27, 2017
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study American Journal of Psychiatry April 16, 2018
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) The International Journal of Neuropsychopharmacology July 9, 2019
and 13 more in the library